Boehringer Ingelheim has become the latest company to enter the growing market of tumour agnostic medicines with the first KRAS inhibitor. …
Boehringer Ingelheim looking to bring tumour-agnostic trials to Australia
October 31, 2019 Latest News
Latest Video
New Stories
-
The COVID-19 vaccine manufacturing and supply deals
September 24, 2020 - - Latest News -
BIO's Joe Damond: US sending industry a signal about pricing in other markets
September 24, 2020 - - Latest News -
New white paper highlights need for action on AMR
September 24, 2020 - - Latest News -
Flu vax: An opportunity to enhance targeted communication
September 24, 2020 - - Latest News -
New report finds Australia lagging on obesity care
September 24, 2020 - - Latest News -
Patient complaint triggers human rights intervention in PHARMAC
September 23, 2020 - - Latest News -
High profile PBS-listed medicines impacted by US executive order
September 23, 2020 - - Latest News